In this coffee chat we discussed one of our team's favorite targets: WRN helicase. During this session, the team delves into why WRN helicase has captured the attention of researchers and unpacked the intricacies of its mechanism of action. They also highlighted an intriguing approach to hit finding that has paved the way for the development of a WRN helicase inhibitor and evaluate compound differentiation.
Don't miss out on future sessions of this new interactive series!
Register here: [ Ссылка ]
Read more on this topic at Drug Hunter: A Covalent Allosteric WRN Helicase Inhibitor Stemming from Chemoproteomics Screening (VVD-214): [ Ссылка ]
Presenters:
Dennis Hu, CEO
Dennis Koester, Director of Industry Research and Relations
Lew Pennington, Scientific Director
Recorded June 21, 2024.
